Immutep
Immutep is a biotechnology company that develops novel immunotherapy treatments for cancer and autoimmune diseases.
Business Model:
Revenue: $5.1M
Employees: 11-50
Industries / Tags:
Detailed Immutep Information
Immutep was acquired by
Prima Biomed.
The acquisition happend on 2014-10-02.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 95 Pitt Street
City: Sydney
State: new south wales
Zip: 2000
Country: AU
Financial Info
Stage:
post ipo equity
Raised Last:
$7M
Raised Total:$12M
Social
Metrics
4,816,950Website Global Rank
1,782Website Monthly Traffic
Twitter Followers
Description
Immutep is a biotechnology company that develops novel immunotherapy treatments for cancer and autoimmune diseases.
Contact Phone:
Contact Email:
Immutep went public on 4/20/2012 on the Australian Securities Exchange
Listed Exchange:
Australian Securities Exchange
IPO Date:
4/20/2012
Ticker Symbol:
IMM
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2018 | Post-IPO Equity | $5.4M | 9/2021 | Unattributed | $2.5M | 12/2018 | Private Placement | $5.2M | 6/2021 | Private Placement | $44.9M | 11/2020 | Private Placement | $21.6M | 4/2020 | Private Placement | $7.8M | 9/2022 | Grant | $1.5M | 7/2019 | Post-IPO Equity | 3 | $6.9M |
Australian Ethical Investment Altium Capital Platinum AM Australian Ethical Investment Altium Capital Platinum AM |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
